Mizoribine
Specifications
50924-49-7CAS Number
637-144-4EC Number
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamideIUPAC Name
C9H13N3O6Chemical Formula
259.22 g/molMolecular Weight
mizoribine; 50924-49-7; Mizoribina; Mizoribinum; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide; DTXSID8045777; 4JR41A10VP; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-; NSC-289637; DTXCID6025777; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide; RefChem:819016; 637-144-4; HE-69; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide; MFCD00057221; MLS000028813; Bredinine; 50524-49-7; SMR000058473; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-b-D-ribofuranosyl-; NCGC00094087-01; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribina [INN-Spanish]; Bredinin (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; CAS-50924-49-7; Mizoribine Hydrobromide; SR-01000075989; BRN 4151713; UNII-4JR41A10VP; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-.beta.-D-ribofuranosyl-; 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; Mizoribine?; NSC 289637;HE 69; Vadadustat 13C6; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; HS-0046; Mizoribine (Standard); N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; MIZORIBINE [MI]; MIZORIBINE [INN]; MIZORIBINE [JAN]; Opera_ID_1558; Spectrum2_001559; Spectrum3_000739; Spectrum4_000220; Spectrum5_001671; Mizoribine (JP17/INN); M 3047; MIZORIBINE [MART.]; SCHEMBL7118; MIZORIBINE [WHO-DD]; Lopac0_000745; BSPBio_002298; KBioGR_000859; MLS001076272; MLS006010038; DivK1c_000948; SPBio_001438; CHEMBL245019; cid_104762; orb1224881; orb1309469; orb3141412; Mizoribine, >=98% (TLC); BDBM68669; CHEBI:31858; HMS502P10; KBio1_000948; KBio3_001518; HZQDCMWJEBCWBR-UUOKFMHZSA-N; NINDS_000948; GLXC-10546; HMS2230D04; HMS3262E12; EX-A2256; Tox21_111242; Tox21_500745; CCG-39778; FD9057; HY-17470R; AKOS015994615; Tox21_111242_1; AC-5266; CS-1823; DB12617; EBC-616626; LP00745; NM09731; NSC 289637; SDCCGSBI-0050723.P004; IDI1_000948; SMP1_000195; NCGC00094087-02; NCGC00094087-03; NCGC00094087-04; NCGC00094087-05; NCGC00094087-09; NCGC00261430-01; BP-58612; HY-17470; SBI-0050723.P003; EU-0100745; M2399; M3598; NS00069262; D01392; AB00053323_12; AB00053323_13; Q6884708; SR-01000075989-1; SR-01000075989-4; BRD-K88061624-001-20-6; BRD-K88061624-001-21-4; 1-(?-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; 1-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; 5-hydroxy-1-b-D-ribofuranosyl-1H-Imidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imidazole-4-carboxamide; 5-HYDROXY-1-.BETA.-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamideSynonyms
